Study protocols are increasingly complex with the need for extensive data collection despite complicated drug regimes. Patients may be deterred from taking part in a trial by the need for frequent travel to a clinical sites and around 30% of patients drop out before study completion, leading to data loss, and potential approval delays.
The new model for Direct to/from Patient and home health care allows visits to be conducted in a patient’s home which improves engagement.
Featured speakers will explore the value of home visits in clinical trials, the benefits gained by both the patient and the sponsor, and how homecare can make a difference to patients’ ongoing participation, quality of life and comfort throughout the trial.
For more information visit www.marken.com